en · de · es · fr · pt
creatine-notes.peptides6908.com › Faq › Molecular Background And Naming — Field Notes

Molecular Background And Naming — Field Notes

By Editorial Desk · published 2025-12-28 · last reviewed 2026-02-05 · Faq

somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-02-05. Numbers and descriptions here follow the published literature rather than marketing material.

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (no linker)~3.37 kDaCalculated from peptide sequence
Molecular weight (with linker)~3.65 kDaIncludes albumin-binding moiety
AppearanceWhite to off-white powderTypically lyophilized
SolubilitySoluble in waterAlso dissolves in aqueous buffers
Common synonymsModified GRF(1-29), DAC:GRFUsage varies by source

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

Related pages on this site

Background and Naming Conventions

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Supporting material

Oral fluphenazine rapidly absorbs and plasma levels peak at about 1.0-2.5 ng/mL 2 hours post-ingestion. The volume of distribution is about 298 L due to extensive tissue uptake, and it crosses the blood brain barrier. Bioavailability is low at 2.7% due to first pass metabolism, and the half-life is about 14–16 hours. Steady state concentrations vary considerably across individuals, which indicates variability in absorption, metabolism, or excretion. Additionally, the dose-level relationship is curvilinear with plasma levels of 0.2 - 2.8 ng/mL being optimal for clinical improvement. Fluphenazine is primarily metabolized to fluphenazine sulfoxide by the cytochrome P450 2D6. Benztropine mesylate did not indicate any major drug-drug interactions. Fluphenazine is exreted primarily through urine and feces. Injectable fluphenazine is dissolved in sesame oil which forms a localized oil depot in the muscle. Due to the lipophilicity of the added decanoate or enanthate group, the drug remains in the oil causing the rate-limiting step for drug being diffusion out, resulting in flip-flop kinetics. Fluphenazine decanoate and enanthate are prodrugs which are hydrolyzed by esterases to fluphenazine. The fluphenazine decanoate acts within 1–3 days, and its effect lasts an average of 2 weeks. The half-life of fluphenazine decanoate is about 6.8-9.6 days, and plasma levels peak at about 2.18 ng/mL about 4–6 hours post injection. Fluphenazine enanthate has a lower half life of about 3.6-3.7 days, reflecting its decreased lipophilicity.

=== Explosives industry === At the 1936 meeting of the American Chemical Society, professor Edward Bartow of the University of Iowa presented a commercially viable means of extracting large amounts of inositol from the phytic acid naturally present in waste corn. As a possible use for the chemical, he suggested 'inositol nitrate' as a more stable alternative to nitroglycerin. Today, inositol nitrate is used to gelatinize nitrocellulose in many modern explosives and solid rocket propellants.

Battle of the Denmark Strait – Naval battle during the Second World War Broad Fourteens – Area of the southern North Sea Communication with submarines – Submarine communication Long Forties – Zone of North Sea Mid-Atlantic gap – Area outside airplane range in World War II SOSUS – Cold War-era passive, fixed array undersea surveillance system Western Approaches – Region of northwestern Atlantic Ocean Luzon Strait – Strait between Luzon and Taiwan Strait of Malacca – Strait between the Malay Peninsula and the Indonesian island of Sumatra Strait of Gibraltar – Strait connecting the Atlantic to the Mediterranean Turkish Straits – Two waterways in Turkey Land:

== Service == Mrksich has also been active in serving the scientific community in a number of roles. These include his current service as the Scientific Director of the Searle Scholars Program, as a member of the Board of Governors for Argonne National Laboratory, and as a member of the Board of Directors for the Camille & Henry Dreyfus Foundation. His past appointments include service and chairing DARPA’s Defense Sciences Research Council and many program advisory committees.

The Popular Front for the Liberation of Bahrain (Arabic: الجبهة الشعبية لتحرير البحرين, romanized: al-Jabha ash-Shaʿbiyya li-Taḥrīr al-Baḥrayn) was an underground political party in Bahrain with origins in the Arab Nationalist Movement. Its members were inclined towards the leftist Marxist trend within the Arab Nationalist Movement. It was created after the Popular Front for the Liberation of Oman and the Arabian Gulf was reconstituted into two separate organizations as the Popular Front for the Liberation of Oman and the Popular Front for the Liberation of Bahrain. Several PFLB members participated in the 1963 to 1976 Dhofar Rebellion in Oman. In 2000, PFLB members established the National Democratic Action Society, the first officially licensed political organization in any of the Arab states of the Persian Gulf. The PFLB was replaced by the NDAS.

Sources: en.wikipedia.org

Notes from published material

=== End of Empire === By this time, the war was closing in on the embattled Emperor. A Union of Czech Deputies had already sworn an oath to a new Czechoslovak state independent of the Habsburg Empire on 13 April 1918; the prestige of the German Army had taken a severe blow at the Battle of Amiens; and, on 25 September 1918, Zita's brother-in-law King Ferdinand I of Bulgaria broke away from his allies in the Central Powers and sued for peace independently. Zita was with Charles when he received the telegram announcing Bulgaria's collapse. She remembered it "made it even more urgent to start peace talks with the Western Powers while there was still something to talk about." On 16 October, the Emperor issued a "People's Manifesto" proposing the empire be restructured on federal lines with each nationality gaining its own state. Instead, each nation broke away and the empire effectively dissolved. Leaving behind their children at Gödöllő, Charles and Zita travelled to the Schönbrunn Palace. By this time ministers had been appointed by the new state of "German-Austria", and by 11 November, together with the Emperor's spokesmen, they prepared a manifesto for Charles to sign. Zita, at first glance, mistook it for an abdication and made her famous statement:

Nitrilotriacetic acid (NTA) is the aminopolycarboxylic acid with the formula N(CH2CO2H)3. It is a colourless solid. Its conjugate base nitrilotriacetate is used as a chelating agent for Ca2+, Co2+, Cu2+, and Fe3+.

Further reading Granger, JP; Alexander, BT; Llinas, M (2002). "Mechanisms of pressure natriuresis". Current Hypertension Reports. 4 (2): 152–9. doi:10.1007/s11906-002-0040-3. PMID 11884271. S2CID 46323264. Hall, J. E.; Mizelle, H. L.; Hildebrandt, D. A.; Brands, M. W. (1990). "Abnormal pressure natriuresis. A cause or a consequence of hypertension?". Hypertension. 15 (6_Pt_1): 547–59. doi:10.1161/01.HYP.15.6.547. PMID 1971810.

Portugal's territory comprises mainland Portugal and the Azores and Madeira archipelagos. The mainland, commonly referred to as Continental Portugal, is located in the southwest of the Iberian Peninsula in Southwestern Europe, while Madeira and the Azores lie in the Atlantic Ocean. Portugal's land area is 92,225 km2 (35,608 sq mi), although Portuguese law defines the country's size as 156,597 km2 (60,462 sq mi) which includes about 64,000 km2 (24,711 sq mi) of ocean waters. Portugal's exclusive economic zone extends 1,727,408 km2 (666,956 mi2), making it one of the largest in the European Union. The country is over two-thirds wilderness, almost one-fourth agricultural, and the remainder human settlements. Portugal's highest point is the summit of Mount Pico, located on Pico Island in the Azores, which rises to an elevation of 2,351 m (7,713 ft) above sea level. Portugal can be divided into four morphostructural units: the Hesperian Massif, which occupies most of mainland Portugal; the sedimentary borderlands of the massif, forming the Lusitanian and Algarve basins; the Lower Tagus and Alvalade sedimentary basins; and the volcanic submarine ranges that form the Azores and Madeira. Its geological and geomorphological features are largely the product of the Variscan, responsible for the formation of the Hesperian Massif, and later the Tethys–Atlantic cycle, responsible for the remaining units.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Why do two versions share one name?

Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.

What is the relationship to GRF(1-29)?

The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.

What is the difference between CJC-1295 and natural GHRH?

Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.

Network